论文部分内容阅读
目的分析酚妥拉明联合促肝细胞生长素治疗慢性重症肝炎的临床疗效。方法 36例慢性重症肝炎患者按照1:1比例分为A组和B组,各18例。A组给予促肝细胞生长素治疗,B组给予酚妥拉明联合促肝细胞生长素治疗,比较两组治疗效果。结果 B组总有效率为94.4%,明显高于A组的44.4%,差异具有统计学意义(P<0.05);两组总胆红素(TBil)均比治疗前降低(P<0.05),凝血酶原活动度(PTA)明显上升(P<0.05),B组TBil、PTA等指标改善情况显著优于A组,差异具有统计学意义(P<0.05)。结论酚妥拉明联合促肝细胞生长素治疗慢性重症肝炎可显著提高PTA,同时降低TBil,疗效确切,值得临床使用和积极推广。
Objective To analyze the clinical efficacy of phentolamine combined with hepatocyte growth-promoting hormone in the treatment of chronic severe hepatitis. Methods Thirty - six patients with chronic severe hepatitis were divided into group A and group B according to the ratio of 1: 1, with 18 cases in each group. A group of patients given hepatocyte growth hormone treatment, B group given phentolamine combined with hepatocyte growth hormone treatment, the two groups were compared. Results The total effective rate in group B was 94.4%, which was significantly higher than that in group A (44.4%), the difference was statistically significant (P <0.05). The total bilirubin (TBil) in both groups was lower than that before treatment (P <0.05) The activity of prothrombin (PTA) increased significantly (P <0.05). The improvement of TBil and PTA in group B was significantly better than that of group A, the difference was statistically significant (P <0.05). Conclusion Phentolamine combined with hepatocyte growth-promoting factor in the treatment of chronic severe hepatitis can significantly improve PTA and reduce TBil, and its curative effect is worthy of clinical use and promotion.